Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can biomarkers flag kidney risk before heart surgery?

NCT ID NCT07811570

Diagnosis Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are studying whether biomarkers in blood, urine, and stool can predict acute kidney injury in adults scheduled for cardiovascular surgery. The trial follows about 1,500 patients, collecting samples and clinical data before and after contrast dye exposure and surgery. By using multi-omics analysis and machine learning, the team aims to identify and validate markers that could one day help doctors spot kidney injury risk earlier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it works, doctors could one day spot kidney injury risk before heart surgery and act sooner, potentially preventing serious complications.
What could go wrong
This is an observational study, so it can only find links between biomarkers and kidney injury, not prove that acting on them helps patients. The biomarkers may not hold up in other hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients scheduled for elective cardiovascular surgery were continuously included in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Age no less than 18 years old; * 2\. Scheduled cardiovascular surgery is proposed; * 3\. Pre-angiography and preoperative serum creatinine \<354 μ mol/L; * 4\. Informed consent. Exclusion Criteria: * 1\. Women who have a pregnancy plan within one year, are pregnant, or are breastfeeding; * 2\. Patients who have severe side effects such as allergies to iodine contrast agents; * 3\. Patients with hyperthyroidism; * 4\. Those who had AKI before the contrast agent or within 2 weeks before the operation, or whose AKI has not been relieved after the operation; * 5\. Patients undergoing kidney transplantation, peritoneal dialysis, or hemodialysis treatment; * 6\. Patients with malignant tumors or those with an expected lifespan of less than 12 months; * 7\. Angiography or preoperative acute heart failure; * 8\. Patients who have a history of massive hemorrhage in the past 30 days or have contraindications to anticoagulant therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Biomarkers Cardiovascular surgery Csa-AKI

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.